title: National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
abstract: The country of Georgia has a high prevalence of hepatitis C virus (HCV) infection, associated with exposures to HCV in health care settings with inadequate infection control and unsafe injections among persons who inject drugs (1). In April 2015, in collaboration with CDC and other partners, Georgia embarked on a program to eliminate HCV infection, subsequently defined as achieving a 90% reduction in prevalence by 2020. The initial phase of the program focused on providing HCV treatment to infected persons with advanced liver disease and at highest risk for HCV-associated morbidity and mortality. By April 27, 2016, a total of 27,392 HCV-infected persons registered for the program, 8,448 (30.8%) started treatment, and 5,850 patients (69.2%) completed HCV treatment. Among patients completing treatment who were eligible for posttreatment testing, 2,398 received polymerase chain reaction (PCR) testing for HCV at least 12 weeks after completion of treatment; 1,980 (82.6%) had no detectable virus, indicative of a sustained virologic response* (i.e., cure). Major challenges to achieving elimination remain, including the need to increase access to care and treatment services and implement a comprehensive approach to prevention and control of HCV infection. As a global leader in this effort, the Georgia HCV Elimination Program can help pave the way for other countries experiencing high rates of HCV infection to undertake similar initiatives.
authors.forename: Lia
authors.initials: L
authors.lastname: Gvinjilia
authors.forename: Muazzam
authors.initials: M
authors.lastname: Nasrullah
authors.forename: David
authors.initials: D
authors.lastname: Sergeenko
authors.forename: Tengiz
authors.initials: T
authors.lastname: Tsertsvadze
authors.forename: George
authors.initials: G
authors.lastname: Kamkamidze
authors.forename: Maia
authors.initials: M
authors.lastname: Butsashvili
authors.forename: Amiran
authors.initials: A
authors.lastname: Gamkrelidze
authors.forename: Paata
authors.initials: P
authors.lastname: Imnadze
authors.forename: Valeri
authors.initials: V
authors.lastname: Kvaratskhelia
authors.forename: Nikoloz
authors.initials: N
authors.lastname: Chkhartishvili
authors.forename: Lali
authors.initials: L
authors.lastname: Sharvadze
authors.forename: Jan
authors.initials: J
authors.lastname: Drobeniuc
authors.forename: Liesl
authors.initials: L
authors.lastname: Hagan
authors.forename: John W
authors.initials: JW
authors.lastname: Ward
authors.forename: Juliette
authors.initials: J
authors.lastname: Morgan
authors.forename: Francisco
authors.initials: F
authors.lastname: Averhoff
mesh_terms: D060740:Disease Eradication; D005845:Georgia / Q000453:epidemiology; D006526:Hepatitis C / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015397:Program Evaluation; D014481:United States / Q000453:epidemiology